Dr. Dennis Slamon, professor of Medicine at JCCC and director of the Revlon/UCLA Women’s Cancer Research Program is the study’s senior author. He says the drug represents a new and “exciting” approach to breast cancer treatment.
In the stage II clinical trials, among 165 breast cancer patients with measureable ER+ disease, 45 percent received the combination had confirmed responses, compared to 31 percent with letrozole alone.
The study showed clinical benefit rates — tumor shrinkage and/or stable disease for a minimum of six months — were 70 percent and 44 percent, respectively.
Lynette Summerill is an award-winning writer and Scuba enthusiast who lives in San Diego with her husband and two beach loving dogs. In addition to writing about cancer-related issues for EmpowHER, her work has been seen in numerous publications.
The Group Room. Richard S. Finn, MD explains Combination Of PD 0332991 and Letrozole Phase II Results at 35th annual CTRC-AACR San Antonio Breast Cancer Symposium. (video)
Combination therapy with experimental drug improves outlook for breast cancer patients. UCLA Jonnson Comprehensive Cancer Center. 2 Dec. 2012. Shaun Mason.
http://newsroom.ucla.edu/portal/ucla/ucla-translational-researchers-241247.aspx and http://newsroom.ucla.edu/portal/ucla/breast-cancer-drug-receives-breakthrough-245162.aspx
Reviewed April 23, 2013
by Michele Blacksberg RN
Edited by Jody Smith